-
公开(公告)号：EP2414395A1
公开(公告)日：2012-02-08
申请号：EP10711526.3
申请日：2010-03-31
发明人： ELKINS, Kristi , POLSON, Andrew , EBENS, Allen , ADAMS, Camelia , ZHENG, Bing , JUNUTULA, Jagath, R. , HONGO, Jo-anne , WU, Yan
IPC分类号： C07K16/28 , A61K39/395 , A61P35/02 , C12N15/13 , C12N5/20 , C07K19/00 , G01N33/574
CPC分类号： A61K39/3955 , A61K31/69 , A61K39/395 , A61K45/06 , A61K2039/505 , C07K16/283 , C07K2317/24 , C07K2317/92 , A61K2300/00
摘要： The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
-
公开(公告)号：EP2414399A1
公开(公告)日：2012-02-08
申请号：EP10722862.9
申请日：2010-03-31
发明人： ELKINS, Kristi , POLSON, Andrew , EBENS, Allen , ADAMS, Camelia , ZHENG, Bing , JUNUTULA, Jagath, R. , HONGO, Jo-anne , WU, Yan
IPC分类号： C07K16/28 , A61K39/395 , A61P35/02 , C12N15/13 , C12N5/20 , C07K19/00 , G01N33/574
CPC分类号： G01N33/6854 , A61K31/138 , A61K31/4196 , A61K31/454 , A61K31/4745 , A61K31/517 , A61K31/56 , A61K31/568 , A61K31/5685 , A61K31/69 , A61K33/24 , A61K38/19 , A61K39/0011 , A61K39/39533 , A61K39/39558 , A61K47/6803 , A61K47/6849 , A61K2039/505 , C07K16/2803 , C07K16/283 , C07K2317/24 , C07K2317/522 , C07K2317/73 , G01N33/574 , G01N33/6857 , Y02A50/473
摘要： The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
-
公开(公告)号：EP2579897A1
公开(公告)日：2013-04-17
申请号：EP11726020.8
申请日：2011-06-07
申请人： Genentech, Inc.
IPC分类号： A61K47/48
CPC分类号： C07K16/00 , A61K47/48376 , A61K47/48569 , A61K47/48715 , A61K47/6803 , A61K47/6811 , A61K47/6817 , A61K47/6829 , A61K47/6855 , A61K51/1051 , C07K16/3092 , C07K16/32 , C07K2317/52 , C07K2317/55 , C07K2319/31
摘要： Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody. Certain highly reactive cysteine engineered antibodies were identified by the PHESELECTOR assay. Isolated cysteine engineered antibodies may be covalently attached to a capture label, a detection label, a drug moiety, or a solid support.
-
4.发明授权
公开(公告)号：EP2144628B1
公开(公告)日：2012-10-17
申请号：EP08747785.7
申请日：2008-05-07
申请人： Genentech, Inc.
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： C07K16/28 , A61K47/6803 , A61K47/6849 , A61K51/1027 , A61K2039/505 , C07K2317/624 , C07K2317/71 , C07K2317/72 , C07K2319/55
-
5.发明公开
公开(公告)号：EP2144628A2
公开(公告)日：2010-01-20
申请号：EP08747785.7
申请日：2008-05-07
申请人： Genentech, Inc.
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： C07K16/28 , A61K47/6803 , A61K47/6849 , A61K51/1027 , A61K2039/505 , C07K2317/624 , C07K2317/71 , C07K2317/72 , C07K2319/55
摘要： Cysteine engineered anti-MUC16 antibodies are engineered by replacing one or more amino acids of a parent anti-MUC16 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-MUC16 antibodies are provided. Cysteine engineered anti-MUC16 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-MUC16 antibody-drug conjugates having Formula I: Ab- (L- D)p where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
-
-
-
-
搜索结果
5 条记录 (耗时 0.026 秒)
